184 related articles for article (PubMed ID: 31478424)
21. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
22. CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies.
Jaiswal SR; Bhakuni P; Aiyer HM; Soni M; Bansal S; Chakrabarti S
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1469-1476. PubMed ID: 32428732
[TBL] [Abstract][Full Text] [Related]
23. New immunotherapy-based approach in allogeneic hematopoietic stem cell transplantation.
Maeda Y
Int J Hematol; 2018 Feb; 107(2):129. PubMed ID: 29260506
[No Abstract] [Full Text] [Related]
24. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
[TBL] [Abstract][Full Text] [Related]
25. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
[TBL] [Abstract][Full Text] [Related]
26. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
Luznik L; Fuchs EJ
Cancer Control; 2002; 9(2):123-37. PubMed ID: 11965233
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
[TBL] [Abstract][Full Text] [Related]
28. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
29. Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity?
Dal-Cortivo L; Ouachée-Chardin M; Hirsch I; Blanche S; Fischer A; Cavazzana-Calvo M; Caillat-Zucman S
Bone Marrow Transplant; 2004 Dec; 34(11):945-7. PubMed ID: 15489880
[TBL] [Abstract][Full Text] [Related]
30. Recent developments in HLA-haploidentical transplantations.
Showel M; Fuchs EJ
Best Pract Res Clin Haematol; 2015; 28(2-3):141-6. PubMed ID: 26590771
[TBL] [Abstract][Full Text] [Related]
31. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
32. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte.
Slavin S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9277-9284. PubMed ID: 37202579
[TBL] [Abstract][Full Text] [Related]
34. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
[TBL] [Abstract][Full Text] [Related]
35. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
[TBL] [Abstract][Full Text] [Related]
36. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
[TBL] [Abstract][Full Text] [Related]
37. Haploidentical stem cell transplantation: the always present but overlooked donor.
Spitzer TR
Hematology Am Soc Hematol Educ Program; 2005; ():390-5. PubMed ID: 16304409
[TBL] [Abstract][Full Text] [Related]
38. Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers.
Krakow EF; Ai HS; Shaffer B; Delisle JS; Hu KX; Sung AD
Curr Drug Targets; 2017; 18(3):281-295. PubMed ID: 25738297
[TBL] [Abstract][Full Text] [Related]
39. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
40. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?
Chang YJ; Huang XJ
Blood Rev; 2013 Jan; 27(1):55-62. PubMed ID: 23261066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
